vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
Clinical hold lifted for late stage cadisegliatin program for diabetesCATT1 Phase 3 trial in patients with type 1 diabetes (T1D) expected to ...
Dyne Therapeutics Announces Appointment of Erick J. Lucera as Chief Financial Officer
Proven financial leader brings decades of experience in capital allocation, business development and shareholder value creation -WALTHAM, ...
vTv Therapeutics Inc.: vTv Therapeutics Announces 2024 Fourth Quarter and Full Year Financial Results and Provides Corporate Update
Clinical hold lifted for late stage cadisegliatin program for diabetes CATT1 Phase 3 trial in patients with type 1 diabetes (T1D) expected to resume Q2 2025 Strengthens commercial leadership with appo ...
Executive Résumé Guide For 2025 And Beyond: How To Land Top C-Suite Roles, By Company Size And Industry
Executive candidates distinguish themselves through résumés and LinkedIn profiles that blend mastery of emerging technologies with proven leadership excellence.